GLP1s and AUD, CVD risk, lipid lowering targets, and status on vaccine for gonorrhea

TT HealthWatch - July 24, 2026
Elizabeth Tracey and Dr. Richard Lange

This week's topics include GLP1s and AUD, impact of CVD risk calculation, meeting lipid lowering targets, and no luck with a vaccine for gonorrhea.

Program notes:

0:38 New guidelines for CVD risk

1:40 21% were reclassified

2:40 More contemporary populations and better data

3:30 Existing meningitis vaccine for gonorrhea

4:30 Incidence in both groups the same

5:30 Randomized trial important

6:18 Prevalence of elevated LDL

7:18 High risk 83% of individuals

8:18 Should be a primary focus

8:30 Taking a GLP1 agonist and AUD

9:30 Did result in fewer hospitalizations for AUD when used

10:30 Relative risk reduction

11:30 Pretty low bar

12:41 End

Next
Next

Continuing dual antiplatelet therapy, Alzheimer's, infections in US hospitals, and algorithms for diagnosing PE